VEGFA and cancer: With the increasing use of antiangiogenic agents for the treatment of cancer, either by blocking the ligand VEGF (ie: Bevacizumab) or by inhibiting the tyrosine kinase domain of VEGF receptors (ie: sorafenib, sunitinib), the measurements of VEGF have become an important tool for the assessment of in vivo efficacy of these agents or their combinations with cytostatic drugs [4, 5, 6].